| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | -0.0065 | 0.9 |
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | 0.0065 | 0.9 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | GSK4112 | CTRPv2 | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | AGK-2 | CTRPv2 | pan-cancer | AAC | 0.0064 | 0.9 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | HBX-41108 | CTRPv2 | pan-cancer | AAC | -0.0069 | 0.9 |
| mRNA | HLI 373 | CTRPv2 | pan-cancer | AAC | -0.006 | 0.9 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0085 | 0.9 |
| mRNA | BRD-K33514849 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.9 |